The bioprocess containers market consists of storage containers and transport containers that are used in the manufacturing of biopharmaceutical products. Bioprocess containers are single-use containers made of materials such as plastic that help maintain sterility and allow for transfer of biologic fluids without any risk of cross-contamination. They are used right from the early stages of cell culture to final fill/finish stages of biopharmaceutical production. Bioprocess containers offer advantages over conventional stainless steel bioreactors as they reduce the complexity and costs associated with cleaning and sterilization of reusable containers. The adoption of single-use technologies is growing across the biopharmaceutical industry as they provide great flexibility of small production batches and help minimize downtime between production runs.

The Global Bioprocess Containers Market is estimated to be valued at US$ 3.67 Bn in 2024 and is expected to exhibit a CAGR of 14.% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the Bioprocess Containers are Cole-Parmer Instrument Company, LLC., ALLpaQ Packaging Group, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Inc., Sartorius AG, Danaher, Entegris, Inc., Avantor, Inc., RIM Bio, Fenner PLC, Lonza, Saint-Gobain, Corning Incorporated. These players are focusing on developing new single-use container solutions to help meet the rising demand from biopharmaceutical manufacturers.

The Bioprocess Containers Market Size is witnessing strong growth due to increasing demand for biologic drugs and growing adoption of single-use technologies by biopharmaceutical companies. Single-use containers help improve productivity and flexibility of bioprocessing. Furthermore, concerns around leachables and extractables from conventional stainless-steel based systems is further driving adoption of single-use containers.

The market is also witnessing significant expansion in emerging regions of Asia Pacific, Latin America, and Middle East & Africa. This is attributable to investment by global biopharma companies to establish new manufacturing facilities in these regions due to availability of low-cost skilled resources. Local players are also developing to cater to domestic demand for bioprocess containers.